Revisiting the steatosis‐associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Jiwon Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Liver Cirrhosis, Asian People, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Research Foundation of Korea, Gilead Sciences Research Scholar Program, Gilead Research Scholars.
Abstract (Originalsprache)
Background and Aim The steatosis‐associated fibrosis estimator (SAFE) score has been developed to distinguish clinically significant fibrosis in patients with steatotic liver disease (SLD). However, validation of its performance in Asian subjects is limited. This study aimed to evaluate the performance of the SAFE score in Asian subjects with biopsy‐proven SLD and in different subgroups according to age, sex, and body mass index.
Methods
We retrospectively analyzed 6383 living liver donors who underwent a liver biopsy between 2005 and 2023. Of these, 1551 subjects with biopsy‐proven SLD were included. The performance of the SAFE score was evaluated using areas under the curve and compared with those of the nonalcoholic fatty liver disease fibrosis score (NFS) and fibrosis‐4 index (FIB‐4).
Results
The prevalence of clinically significant fibrosis in the cohort was 2.2%. The proportion of subjects with a “low‐risk” SAFE score was the highest (91.0%), followed by those with “intermediate‐risk” (7.8%) and “high‐risk” (1.2%) scores. The prevalence of fibrosis in subjects with low‐risk, intermediate‐risk, and high‐risk scores was 1.6%, 6.6%, and 21.1%, respectively. The SAFE outperformed FIB‐4 and NFS (area under the curve: 0.70 vs 0.64 for both NFS and FIB‐4). However, it showed low diagnostic accuracy and sensitivity (27%) at the low cutoff (SAFE < 0) in subjects aged 30–39 years (fibrosis: 1.2%), despite having a high negative predictive value (0.99).
Conclusion
While the SAFE score demonstrates superior performance compared with other noninvasive tests in Asian subjects with SLD, its performance varies across age groups. In younger subjects, particularly, its performance may be more limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Won-Mook Choi, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Förderung
- National Research Foundation of Korea
- Gilead Sciences Research Scholar Program
- Gilead Research Scholars
Zitieren
APA
Yang, J., Choi, W. M., Lee, D., Shim, J. H., Kim, K. M., Lim, Y. S., Lee, H. C., & Choi, J. (2024). Revisiting the steatosis‐associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16656
Vancouver
Yang J, Choi WM, Lee D, Shim JH, Kim KM, Lim YS, et al. Revisiting the steatosis‐associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16656
BibTeX
@article{Yang2024,
author = {Yang, Jiwon and Choi, Won-Mook and Lee, Danbi and Shim, Ju Hyun and Kim, Kang Mo and Lim, Young-Suk and Lee, Han Chu and Choi, Jonggi},
title = {Revisiting the steatosis‐associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16656}
}
EUVIMED